key: cord-1048039-jogrylm6
authors: Xiang, Yufei; Huang, Wei; Liu, Hejun; Sang, Zhe; Nambulli, Sham; Tubiana, Jérôme; Williams, Kevin L; Duprex, W Paul; Schneidman-Duhovny, Dina; Wilson, Ian A.; Taylor, Derek J.; Shi, Yi
title: Super-immunity by broadly protective nanobodies to sarbecoviruses
date: 2021-12-28
journal: bioRxiv
DOI: 10.1101/2021.12.26.474192
sha: c6eea314259fdfae61be66e912d3334add840cca
doc_id: 1048039
cord_uid: jogrylm6

Vaccine boosters and infection can facilitate the development of SARS-CoV-2 antibodies with improved potency and breadth. Here, we observed super-immunity in a camelid extensively immunized with the SARS-CoV-2 receptor-binding domain (RBD). We rapidly isolated a large repertoire of specific ultrahigh-affinity nanobodies that bind strongly to all known sarbecovirus clades using integrative proteomics. These pan-sarbecovirus nanobodies (psNbs) are highly effective against SARS-CoV and SARS-CoV-2 variants including the Omicron, with the best median neutralization potency at single-digit ng/ml. Structural determinations of 13 psNbs with the SARS-CoV-2 spike or RBD revealed five epitope classes, providing insights into the mechanisms and evolution of their broad activities. The highly evolved psNbs target small, flat, and flexible epitopes that contain over 75% of conserved RBD surface residues. Their potencies are strongly and negatively correlated with the distance of the epitopes to the receptor binding sites. A highly potent, inhalable and bispecific psNb (PiN-31) was developed. Our findings inform on the development of broadly protective vaccines and therapeutics. One sentence summary Successive immunization of SARS-CoV-2 RBD in a camelid enhanced the development of super-immunity and isolation and systematic characterization of a large repertoire of ultrahigh-affinity pan-sarbecovirus single-chain VHH antibodies to understand the evolution of this potent and broad immune response.

with strong and broad activities against the full spectrum of sarbecoviruses (Fig. 1, A and B) . The relative binding affinities (ELISA IC 50 s) for RBDs from clade 1a (RBD SARS-CoV ), 2 (RBD RmYN02-CoV ), and 3 (RBD BM-4831-CoV ) were 0.08, 0.09, and 0.14 nM, respectively, which correspond to 8.5, 7.2, and 8.6 fold improvements over the initial bleed ( fig. S1A ).

Next, we employed quantitative Nb proteomics (15) to identify high-affinity psNbs that confer broadspectrum activity in immunized sera (see Methods). This technology rapidly identified hundreds of distinct CDR3 families, from which a fraction of highly divergent Nbs were expressed and characterized. A total of 100 Nbs that interacted strongly with RBD SARS-CoV-2 (Clade 1b) were confirmed to cross-react with other sarbecovirus clades (Fig. 1C, table S1 ). Of these, 23%, 35%, and 42% were found to bind two, three, and all four sarbecovirus clades, respectively. Consistent with total polyclonal V H H activity, psNbs isolated from the booster show broader pan-sarbecovirus activity than the initial bleed ( fig. S2B) . A substantial fraction (42%) was able to potently neutralize SARS-CoV-2 below 500 nM, with the best IC 50 of 1.2 ng/ml (77 pM, 2-67) , and a median of 0.25 µg/ml (17 nM) (table S1). Network analysis revealed that the psNbs are dominated by multiple clusters that span a large spectrum of physicochemical properties including isoelectric point (pI) and hydropathy (Fig. 1D, fig. S2A ). The three largest clusters are each composed of potent neutralizers (with the best IC 50 of 6.8 ng/ml) that bind strongly to at least three sarbecovirus clades (table S1). A smaller cluster (represented by 2-62 and 2-63) showed broad activity, yet only weakly neutralized SARS-CoV-2 in vitro (IC 50 s between 40 -132 µg/ml, table S1, fig. S6 ). Other small clusters represented by 2-19, 2-16, 2-3 and 2-24 did not show neutralization at up to 37.5 µg/ml.

The psNbs were further classified by epitope binning using size exclusion chromatography (SEC).

psNb-RBD SARS-CoV-2 complexes were competed with high-affinity benchmark Nbs (Nb21, Nb105, and Nb36) that bind distinct and well-characterized epitopes (16) (fig. S3, A and B, Methods) . psNbs fall into five groups: group A (3%) competes with Nb21 and targets RBS, group B (33%) with Nb105, group C (9%) with Nb36, and group D (17%) does not compete with any benchmark Nbs. Approximately one third of psNbs (Group E, 38%) bind strongly to RBDs based on ELISA, but do not neutralize pseudotyped SARS-CoV-2 efficiently. We selected a high-affinity psNb from group E and confirmed its strong binding to the fully glycosylated but not the de-glycosylated RBD ( fig. S3C, Methods) . It is possible that 2-47 can target an epitope encompassing the conserved, glycosylated RBD residue(s) (e.g., N343) (17) . Together, these experiments suggest that a large cohort of high-affinity and divergent psNbs targeting multiple dominant RBD epitopes contribute to the broad-spectrum serologic activities.

17 psNbs spanning four SEC groups (A-D) were tested for binding to RBDs of five SARS-CoV-2 variants, including the fast-spreading Omicron, and other 18 different sarbecovirus RBDs. These psNbs bind strongly to all variants that were evaluated. 16 of the 17 psNbs bind to all four clades ( Fig. 2A) . Interestingly, seven psNbs (such as 2-31 and 2-45) have exceptionally broad activities and bind strongly to all 24 RBDs with a median ELISA IC 50 of 3 nM ( Fig. 2A, fig. S4 , table S1). Two representative psNbs were measured for binding kinetics to all four clades by SPR. The K D s of 2-31 for RBD SARS-CoV-2 (Clade 1b), RBD SARS-CoV (clade 1a) , RBD RmYN02-CoV (clade 2) , RBD BM-4831-CoV (clade 3) are <1 pM, 3.96 pM, 0.59 nM and 3.60 nM, respectively (Fig.   2D, fig. S7, A and B) . The binding of 2-45 is equally strong for clades 1b, 2 and 3 (0.39 nM, 1.4 nM and 44 pM,respectively) and more moderate for clade 1a (304 nM) (Fig. 2E, fig. S7, C and D) . Of note, these psNbs are highly specific to sarbecoviruses and do not cross-react with a human whole protein extract at high concentrations (up to 8 µM) ( Fig. 2A) .

All but one of these 17 psNbs can potently inhibit SARS-CoV-2 and VOCs in vitro, based on a pseudovirus assay, and plaque reduction neutralization test (PRNT) against the Munich strain and Delta VOC (Fig. 2B and C, figs. S5 and S6, Methods) . Group A Nb 2-67, which preferentially binds to clade 1b, is extremely potent for SARS-CoV-2 and VOCs with a median neutralization potency of 1.2 ng/ml. Group C (1-22, 2-10 and 2-45) neutralizes VOCs at single-digit µg/ml, but is less effective against SARS-CoV. 2-63 (group D) has exceptional breath while the other group D psNb 2-28 has limited breadth. Both weakly neutralize SARS-CoV-2 (IC 50 7 -132 µg/ml). The remaining psNbs belong to group B and show comparably high potency against SARS-CoV. The median potency for SARS-CoV-2 and VOCs is 86 ng/ml with the most potent (2-55) at 6 ng/ml. Notably, psNbs are usually highly stable and can withstand aerosolization without compromising activity as exemplified by 2-31 and 2-45 (Fig. 2F, fig. S7, E and F, Methods) . To demonstrate the high bioengineering potentials of psNbs, we developed a bispecific construct (PiN-31) by fusing these two potent and broadspectrum psNbs, which cover two distinct epitopes based on SEC. Compared to the monomers, the potency of PiN-31 improves by an order of magnitude to 0.4 nM based on the PRNT assay (Fig. 2G) .

To understand the mechanisms of broad neutralization, we implemented cryoEM to interrogate the structures of 11 psNbs in complex with the SARS-CoV-2 spike or RBD (table S2) . Additionally, two atomic psNb: RBD structures were determined by X-ray crystallography (table S3). Epitope clustering based on high-resolution structures revealed five primary and distinct epitope classes in RBD SARS-CoV-2 (Fig. 3A) . None of our psNbs (except for 2-57) overlap with key RBD mutations in variants including Alpha, Beta, Delta, Lambda, Gamma, and Omicron (Fig. 3B) , in contrast to most other Nbs that have been structurally characterized (18) (19) (20) (21) (22) (23) (24) (25) (fig. S8) .

Over three-quarters of the solvent-exposed and highly conserved RBD residues (sequence identity > 85%) are covered by psNbs (see Methods). Superposition onto the spike structure reveals that psNbs preferentially lock RBDs in the 3-up conformation (Fig. 3C) . Despite having different epitopes and orientations, the small size of Nbs facilitates simultaneous binding of three copies to the spike trimer in distinct and highly symmetric configurations.

The Class II psNbs are overrepresented in our collection. Phylogenetic analysis reveals that while psNbs are diverse, those isolated from the booster converge more than the initial bleed (Fig. 4A) . Two subclasses within the class II (A and B) differ in epitopes and Nb binding orientation (Fig. 4, B and D) .

Nevertheless, II(A) and II(B) psNbs share a conserved hydrophobic core epitope (aa 377-386) (Fig. 4C) containing two bulky hydrophobic residues (F377 and Y380), and this region is stabilized by a disulfide bond (C379-C432). The improved breadth in class II(B) psNbs, especially for clade 3 RBD BM-4831-CoV lies in its ability to target an additional conserved region with peripheral charged residues (aa 412-415, 427-429). In contrast, subclass II(A) psNbs bind to a less conserved epitope that is composed of primarily hydrophobic residues (e.g., L368, A372, and Y508) (Fig. 4C) . Notably, A372 on SARS-CoV-2 (clade 1a) is substituted to S/T in other clades, forming a consensus glycosylation motif ( 370 NST/S 372 ) (26), which may explain the reduced neutralization potency of class II (A) psNbs versus class (B) psNbs against SARS-CoV (Fig. 2B, 4B ).

Class II(B) psNbs comprise two large clusters possessing the best breadth and potency (Fig. 1D) .

While the epitopes largely overlap in the complex structure, the molecular interactions vary substantially. For example, two related psNbs (2-38 and 1-21) are characterized by a short CDR3 (13 aa) forming a β-strand hairpin conformation. Yet, psNb 2-38 is an all-clade binder whereas 1-21 binds strongly to all but RBD BM-4831-CoV (clade 3). The difference in binding is likely due to the K378Q substitution in the RBD, which disrupts a critical salt bridge between D110 (1-21) and K378 (RBD SARS-CoV-2 ) (Fig. 4E, fig. S9B , S12, A and B). psNbs 2-34 and 2-31 (from the other dominant cluster) bind all 24 RBDs strongly with potent antiviral activities. The interactions are predominantly mediated by a long CDR3 loop (18 aa) with a small helix. These Nbs form hydrophobic interactions and also bind strongly to conserved charged residues (such as D427 and R408) through electrostatic interactions (Fig. 4F, fig. S9A , S12, C and D).

Class II(A) psNb (2-57) shares high sequence similarity with Nb105 (isolated from the initial bleed).

The major difference lies in their CDR3 heads. Here, a small CDR3 loop of 109 DLF 111 in Nb105 is substituted by 109 QST 111 in 2-57, which inserts into two conserved pockets (RBD residues F377,Y369,F374 and residues S375,T376,Y508,V407) forming extensive hydrophobic interactions with the RBD (Fig. 4G, fig. S10 , S11, S12E). This substitution allows psNb 2-57 to tolerate sequence variation better, exhibiting over 100 fold higher affinities for clade 2 RBDs (table S1).

Class I psNbs that bind the RBS are extremely potent yet rare (~3%). The structure of the ultrapotent (Fig. 5B, fig. S15A ). Binding energy analysis (Methods) reveals that compared to other RBS Nbs (18) (19) (20) (21) (22) (23) (24) (25) , the RBD binding epitope of 2-67 is minimally contributed by critical VOC residues (Fig. 5C, table S5 ).

Here, 2-67 utilizes all CDRs to form extensive networks of hydrophobic and nonpolar interactions with two critical RBD residues that are not present as VOC mutations (F486 and Y489), and therefore, can achieve ultrahigh affinity for SARS-CoV-2 and retain strong binding and neutralization against the variants (Fig. 5D) .

Moreover, 2-67 can outcompete ultrahigh-affinity Nb21 for RBS binding, thereby further corroborating the ultrahigh affinity of this interaction ( fig. S14A) (14) . Interestingly, quantitative mass spectrometric analysis reveals that ultrapotent RBS binders (e.g., Nbs 20 and 21) identified from the initial bleed were absent in the booster, implying that they are sourced from short-lived plasma cells (28) (fig. S14B ).

Class III psNb (2) (3) (4) (5) (6) (7) (8) (9) (10) can destabilize the spike in vitro as we observed previously (16) . However, the structure can be resolved by reconstituting an RBD: 4 Nbs complex by cryoEM (Methods, fig. S13 ). 2-10 targets a rare non-RBS epitope that partially overlaps with that of Nb17 (Fig. 5E ) isolated from the initial bleed that is partially effective against variants (16) . Class III psNb binds strongly to RBD variants and clade 1b and shows selectivity within other clades. Compared to Nb17 with limited breadth, the improved breadth of class III psNb is contributed by a recognition motif that shifts (from aa 356-357 to aa 449-450,481-484 and 490-494) towards a smaller and more conserved epitope (Fig. 5F, fig. S15B ).

Four Class IV psNbs (1-22, 1-23, 2-65 and 2-45) were resolved by cryoEM. Their binding involves a plethora of molecular contacts that are dependent upon distinct scaffold orientations, different CDR combinations and sequence-specific bonding networks. Class IV shares a highly conserved and cryptic epitope that is only accessible in the RBD-up conformation (Fig. 3, A and C, Fig. 5G ). The epitope is characterized by charged and hydrophobic residues (D427/D428, T430, F464, 516 ELLH 519 ) forming a cavity (Fig. 5G) . CDR3s of class IV adopt a "hairpin" conformation that inserts into the RBD cavity forming extensive hydrophobic and shows selectivity towards clade 1b and clade 3 likely due to a unique salt bridge between D124 (CDR3) and the semi-conserved H519 on RBDs ( fig. S15E) . Notably, the class IV epitope partially overlaps with a newly discovered broadly neutralizing antibody S2H97(10) and targets RBD from a distinct angle ( fig. S16 ).

Compared to S2H97 which depends on bulky aromatic side chains (W, F, and Y) for interaction, the binding of 1-22 is primarily mediated through a combination of hydrophobic, non-aromatic (L, I, and V), and basic (R and H) residues. Facilitated by a unique orientation, Class V psNb (2-62, which shares high CDR similarity with 2-63) targets RBD through a conserved epitope (T333,L387, 389 DLC 391 , C525, L517, and P521) completely buried in the spike and a region that marginally overlaps with the binding motif of class IV psNbs (i.e., L517 and H519) 

Our comprehensive investigation provides direct evidence that with successive immunization, antibodies emerged in the serum that concurrently and almost exhaustively target diverse and conserved physicochemical and geometric sites on the RBD. We observed that ultrahigh-affinity Nbs (i.e., sub-nM) exhibit neutralization potencies that correlate inversely, almost perfectly, with distance of their epitopes from the RBS (Fig. 6, A and B, Methods) . Ultrapotent class I psNbs neutralize the virus at single-digit ng/ml by binding to the RBS to block hACE2 binding ( fig. S17) . Class II psNbs can still efficiently neutralize the virus (i.e., singledigit ng/ml) primarily by sterically interfering with the receptor binding. In particular, binding to the RBD can clash with the glycan moiety at N322 of hACE2, especially bulky complex-type glycans (29) ( fig. S17 ). Class III, IV and V possess substantially weaker potencies. Their epitopes are distant from RBS and do not compete with hACE2 in vitro.

To better understand the broad activities of psNbs, we also expressed a set of high-affinity RBD Nbs that have been previously characterized (18) (19) (20) (21) (22) (23) (24) (25) and evaluated cross-reactivity by ELISA (table S4, Methods).

Nbs fall into two groups based on RBS occupancy. Overall, their cross-reactivities positively correlate with epitope sequence conservation (Fig. 6C) . psNbs that do not bind the RBS can be separated based on high epitope conservation (>0.85) (Fig. 6D) . Critical mutations from the variants are predominantly located on the RBS but also recently on a small patch of relatively conserved residues (e.g., aa 371, 373 and 375) in Omicron (B.1.1.529). Additionally, the virus can mutate on A372S/T to acquire an N-linked glycan (N370) similar to other sarbecoviruses to blunt the host antibody response (30). While most Nbs and human IgGs directly interact with these residues, psNbs are barely affected ( Fig. 2A-B, fig. S5 ). Mutations on these highly conserved epitopes can cause RBD instability reducing viral fitness (31) (Fig. 6E) .

Compared to RBS Nbs that bind to concave epitopes, psNbs generally target smaller (Fig. 6H ) and flat (class II,III and V) or convex (class I and IV) regions (Fig. 6F) . psNb epitopes are also more flexible based on average root-mean-square-fluctuation (RMSF) for epitope residues (Fig. 6G, table S5, Methods) . Together, these properties may render high-affinity binding particularly challenging. Consistently, ScanNet, a geometric deep-learning model reveals that RBS epitopes are predominantly targeted by Nbs (and IgG antibodies) while the psNb epitopes are hardly recognized ( fig. S19) . Moreover, compared to non-psNbs, psNbs utilize almost exclusively hypervariable CDR loops ( fig. S18) . Conceivably, extensive affinity maturation is required to bind these conserved yet difficult-to-bind epitopes.

SARS-CoV-2 continues to evolve, producing variants with high transmissibility and potential to evade host immunity (32, 33). New evidence indicates that infection or vaccination by boosting can improve the host antibody response against SARS-CoV-2 variants (3-7). Here we discovered that successive immunization of a camelid by recombinant RBD can enhance the development of super-immunity. Integrative proteomics facilitated rapid identification of a large repertoire of high-affinity V H H antibodies (Nbs) from the immunized sera against SARS-CoV-2 VOCs and the full spectrum of sarbecovirus family. CryoEM and X-ray crystallography were able to systematically map broadly neutralizing epitopes and interactions, providing insights into the structural basis and evolution of serologic activities. Our data support the notion that RBD structure alone can drive this impressive level of evolution, reshaping the immunogenic landscape towards conserved epitopes.

The initial immune response predominantly targets the RBS due to its favorable properties for protein-protein interactions (both host receptor and antibody binding). High-affinity antibodies can evolve to saturate this critical region with extremely high neutralization potency. However, broadly neutralizing antibodies will emerge (with unprecedented diversity) and can continuously develop improved affinity to target conserved epitopes, which provide resistance to antigenic drift. Their neutralization potencies vary substantially yet are strongly and negatively correlated with the distance of epitopes to the RBS-center for viral entry and effective host immunity.

Together, our findings inform on the development of safe and broadly protective countermeasures such as vaccines and therapeutics.

Preference for non-conserved epitopes is also observed in other viral antigen structures ( fig. S20 ). We suggest that evolutionary conservation imposes constraints on spatio-chemical surface properties, which in turn constraints the immunogenicity of and access to epitopes, as hinted by an overall negative correlation between conservation and predicted epitope propensity ( fig. S21) . However, antibody repertoires are dynamic and can evolve towards conserved epitopes. In addition to COVID-19 super-immunity, potent broadly neutralizing antibodies have also been isolated from HIV elite controllers, although they usually take years to evolve (34).

Our highly selected psNbs can bind strongly and specifically to all sarbecoviruses for potent neutralization with the best median antiviral potencies at single-digit ng/ml, which is extremely rare for cross- 

Tables S1-S5

References 43-86 Breadth of sarbecovirus RBD binding is indicated by the filled gradient color (table S1) and the SEC epitope groups (based on benchmark RBD Nbs) are colored on the outer circle ( fig. S3, a and b) . The highest Nb concentration used for binding and neutralization was 8 µM and 2.5 µM, respectively. Bolded psNbs were selected for downstream characterizations. psNbs isolated from the initial and booster bleed were denoted as 1-, and 2-respectively. 

The mammalian expression vectors (43) 

A llama ("Wally") was immunized with an RBD-Fc fusion protein (Acro Biosystems, Cat#SPD-c5255) at a primary dose of 0.2 mg (with complete Freund's adjuvant), followed by three consecutive boosts of 0.1 mg every 2 weeks. The initial bleed was collected 10 days after the final boost as previously described (14) . Three weeks after the collection of the initial bleed, the llama was immunized again by four consecutive boosts every 2 weeks. The booster bleed was collected 10 days after the final boost. The immunization procedures were performed by Capralogics, Inc. following the IACUC protocol.

To isolate V H H antibodies, plasma was first purified from the immunized bleeds by the Ficoll gradient (Sigma).

Polyclonal V H Hs mixtures were then isolated from the plasma using a two-step purification protocol (45) . RBDs from 4 sarbecovirus clades (RBDSARS-CoV-2, RBDSARS-CoV, RBDRmYN02 and RBDBM-4831) were coupled to the CNBractivated sepharose resin for affinity isolation of RBD-specific V H Hs. After binding, RBD-specific V H Hs were eluted and proteolyzed as previously described (14, 15) . Efficiently digested peptides were subjected to proteomics analysis by using the nano-LC 1200 that was coupled online with a Q Exactive™ HF-X Hybrid

Quadrupole Orbitrap™ mass spectrometer. The MS data obtained from different RBD-specific V H H isolations were analyzed by AugurLlama to identify high-affinity Nbs for each RBD (15) . To facilitate the identification of psNbs, the abundance of Nb CDR3 peptides was quantified across different V H H isolations. psNbs (represented by CDR3s) are assigned based on two criteria. 1) they must be classified as high-affinity binders for RBD SARS-CoV-2 . 2) In addition, they must appear in at least one more RBD isolation sample and are not classified as low affinity binders (15) .

The monomeric Nb genes were codon-optimized and synthesized (Synbio). All the Nb DNA sequences were cloned into a pET-21b(+) vector using EcoRI and HindIII restriction sites. The monomeric Nbs 2-31 and 2-45

were also cloned into a pET-22b(+) vector at the BamHI and XhoI sites for periplasmic expression. To produce a heterodimeric Nb 132-118, the DNA fragment of the monomeric Nb 2-31 was first PCR amplified from the pET-21b(+) vector to introduce a linker sequence and two restriction sites of XhoI and HindIII that facilitate cloning:

Primer1: cccAAGCTTggtggtggtggtagtggtggtggtggtagtggtggtggtggtagtCAaGTTCAACTGGTTGAATCTG;

Primer2: ccgCTCGAGTGCGGCCGCcagtttGCTACTAACGGTAACTT.

The PCR fragment was then inserted into the 2-45 pET-21b(+) vector at the same restriction sites to produce the heterodimer 2-45-(GGGGS) 3 -2-31.

Nb were collected by centrifugation and subsequently dialyzed to DPBS. The resulting Nbs were then purified by

Cobalt resin as described above.

Indirect ELISA was carried out to evaluate the camelid immune responses of the total single-chain only antibody (V H H) to an RBD and to quantify the relative affinities of the psNbs. A 96-well ELISA plate (R&D system) was coated with the RBD protein or the HEK-293T cell lysate at an amount of approximately 3-5 ng per well in a coating buffer (15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6) overnight at 4°C, with subsequent blockage with a blocking buffer (DPBS, v/v 0.05% Tween 20, 5% milk) at room temperature for 2 hours. To test the immune response, the total V H H was serially 5-fold diluted in the blocking buffer and then incubated with the RBD-coated wells at room temperature for 2 hours. HRP-conjugated secondary antibodies against llama Fc were diluted 1:75,00 in the blocking buffer and incubated with each well for an additional 1 hour at room temperature. For the initial screening of Nb binding against 4 RBDs, scramble Nbs that do not bind the RBDs were used as negative controls. Nbs were serially 10-fold diluted from 1 μM to 1 nM in the blocking buffer. For the Nb affinity measurements against 24 RBDs, Nbs were serially 4-fold diluted. The dilutions were incubated for 2 hours at room temperature. HRP-conjugated secondary antibodies against the T7-tag were diluted at 1:5,000 or 1:75,00 in the blocking buffer and incubated for 1 hour at room temperature.

Three washes with 1x PBST (DPBS, v/v 0.05% Tween 20) were carried out to remove nonspecific absorbances between each incubation. After the final wash, the samples were further incubated in the dark with freshly prepared w3,3′,5,5′-Tetramethylbenzidine (TMB) substrate for 10 mins at room temperature to develop the signals. After the STOP solution (R&D system), the plates were read at multiple wavelengths (450 nm and 550 nm) on a plate reader (Multiskan GO, Thermo Fisher). The raw data were processed by Prism 9

(GraphPad) to fit into a 4PL curve and to calculate logIC 50 .

A 96-well plate was pre-coated with recombinant spike-6P at 2 µg/ml at 4°C overnight. Nbs were 5-fold diluted 

Analytical size exclusion chromatography was performed with a Superdex 75 increase GL column (column volume: 24 mL, Cytiva) on a Shimadzu HPLC system equipped with a multi-wavelength UV detector at a flow rate of 0.3 mL/min. The column was connected and placed in a column oven set to 15 °C, and the SEC running buffer was 10 mM HEPES pH 7.1, 150 mM NaCl. A reference SEC profile for RBD with epitope I benchmark Nb (Nb21), epitope II benchmark Nb (Nb105) and epitope III benchmark Nb (Nb36) was performed after column equilibration. Subsequently, three separate runs with RBD and specified psNb were performed after mixing with (i) benmark I and benchmark II, (ii) benchmark II and III and (iii) benchmark I and III Nbs. A supershift of the peak, at the same or to the left of the RBD and three Nbs peak in the reference profile, in run (i) but not run (ii) and (iii) sorts a psNb into group C. Similarly, psNb with a supershift in run (ii) but not run (i) and (iii) belongs to group A, and a supershift in run (iii) but not run (i) and (ii) belongs to group B. When supershifts were observed in all three runs, the psNb was sorted into a group D. psNbs were sorted into group E if the supershifts were not detected on SEC.

Surface plasmon resonance (SPR, Biacore 3000 system, GE Healthcare) was used to measure Nb affinities. 

The 293T-hsACE2 stable cell line (Cat# C-HA101, Lot# TA060720C) and pseudotyped SARS-CoV-2 (Wuhan- was measured using the Renilla-Glo luciferase assay system (Promega, Cat# E2720) with the luminometer at 1 ms integration time. The obtained relative luminescence signals (RLU) from the negative control wells were normalized and used to calculate the neutralization percentage at each concentration. Data were processed by Prism 9 (GraphPad) to fit into a 4PL curve and to calculate the logIC 50 (half-maximal inhibitory concentration).

Nbs Standards and Control, UK) and an uninfected cells control were also used to ensure that virus neutralization by antibodies was specific.

All work with SARS-CoV-2 was conducted under biosafety level-3 (BSL-3) conditions in the University of Pittsburgh Center for Vaccine Research (CVR) and the Regional Biocontainment Laboratory (RBL).

Respiratory protection for all personnel when handling infectious samples or working with animals was provided by powered air-purifying respirators (PAPRs; Versaflo TR-300; 3M, St. Paul, MN). Liquid and surface disinfection was performed using Peroxigard disinfectant (1:16 dilution), while solid wastes, caging, and animal wastes were steam-sterilized in an autoclave.

Nb was eluted and collected in the SEC running buffer (20 mM HEPES, 150 mM NaCl, pH 7.5) and then concentrated to 0.5 ml (1 mg/ml). Nb was aerosolized by using a portable soft mist inhaler Pulmospray® (Resyca). Around 0.1 -0.15 ml dead volume was observed in the syringe and connector. The aerosols were collected in a 50 ml falcon tube and SEC analysis was performed as described above.

SARS-CoV-2 HexaPro spike at 1.1 mg/mL was incubated with 1.5-fold molar excess of specified Nbs at room temperature for two hours. 3.5 μL of 1 to 3 dilution sample using HBS buffer with 1% glycerol was applied onto a freshly glow discharged UltraAuFoil R1. For PNCC datasets, movie stacks were recorded using an FEI Titan Krios transmission electron microscope G3i operated at 300 keV and equipped with a Gatan K3 direct electron detector and Gatan

BioContinuum image filter operated in zero-loss mode with a slit width of 20 eV. Automated data collection was carried out using serialEM (46) at a nominal magnification of 64,000x with a physical pixel size of 1.329 Å/pixel (0.6645 Å/pixel at super-resolution). The dose rate was determined over a sample hole to calculate the exposure time resulting in a total dose of 40 e/Å 2 and the exposures were fractionated into a total of 40 frames.

The number of movies for a specified dataset was listed in table S2. The defocus range was set to between -0.5 and -2 μm.

Image processing was performed on-the-fly using CryoSPARC Live version 3.2 (47) (48) (49) . The particles were automatically picked using the blob picker with 240 Å or 100 Å diameter for spike:nanobody or RBD:nanobodies, respectively. Reference-free 2D classification was performed in streaming with 200 classes and limited maximum resolution to 18 Å. Upon the completion of data collection, the selected particles from the good 2D class averages were subjected for another round of 2D classification with 200 classes, and particles from classes with resolution better than 10 Å and ECA less than 2 were selected for subsequent analysis.

These 2D classes were submitted for a "rebalance 2D" job type to trim particles from dominant views. The rebalanced particle set was then used for ab-initio reconstruction to generate the initial volume. 3D refinement was first carried out using non-uniform refinement using ab-initio volume as the reference without mask. To resolve the density for nanobodies, an RBD structure (PDB 6M0J) (27) was docked into the cryoEM density and the structural model for nanobody was manually placed into the additional density accounted for nanobodies to ensure the correct orientation. The resulting RBD:nanobody model was used to generate the mask for focused 3D classification in CryoSPARC version 3.3.1 with six classes and target resolution of 6 Å, and PCA was chosen as the initialization mode with the parameter "number of components" set for 2. 3D classes with both RBD and nanobody densities well resolved were selected for sequent new local refinement with the mask around RBD and nanobody. The gold-standard Fourier shell correlation (FSC) of 0.143 criterion was used to report the resolution and the FSC curves were corrected for the effects of a soft mask using highresolution noise substitution (50) .

PDB entry, 7CAK (51) , was used as the initial model for spike excluding RBD and the missing fragment for residues 621 to 640 was modeled de novo in Coot (52) . RBD from PDB entry, 6M0J (27), was used as the initial model and nanobodies structures were generated using ColabFold (53) . After assembling individual components into a single PDB file, the models were refined into the composite map using phenix.real_space_refine (54) . The glycans were built using the carbohydrate module in Coot (55) . Models were manually corrected in Coot (version 9.6.0) between rounds of read-space refinement in Phenix. All statistics for structural models were reported in table S2. Fig. panels depicting cryoEM maps or atomic models generated using ChimeraX (56) . Maps colored by local resolution were generated using RELION 3.1 (57).

Molecular dynamic (MD) simulations were used to generate short 1 ns trajectories for relative binding energy calculation. Input files for MD simulations of SARS-CoV-2 RBD and nanobody complexes (table S5) were prepared using tleap (58) . MD simulations were performed using the NAMD (59) and the amber ff19sb (60),

GLYCAM_06j (61), ions with the TIP3P water model (62) . Proteins were solvated in a cubic water box with a 16 Å padding in all directions. Sodium ions and chloride ions were added to achieve a physiological salt condition of 150 mM. The systems were energy minimized for 10,000 steps to remove bad contacts. Then, the systems were equilibrated with all heavy atoms restrained harmonically and the temperature raised 10 K per 10,000 steps starting from 0 to 300 K using temperature reassignment. After reaching the desired temperature, harmonic restraints were gradually reduced using a scale from 1.0 to 0 with a 0.2 decrements for every 50,000

steps. MD simulations were performed under the NPT ensemble (63, 64) . Langevin dynamics was used for constant temperature control, with the value of Langevin coupling coefficient and the Langevin temperature set to 5 ps and 300 K, respectively. The pressure was maintained at 1 atm using the Langevin piston method with a period of 100 fs and decay times of 50 fs. A time step of 2 fs was used for all the simulations by using the SHAKE algorithm (65) to constrain bonds involving hydrogen atoms. 

where is the molecular mechanic (MM) interaction energy calculated in gas-phase between RBD and nanobody, including electrostatic and van der Waals energies; the desolvation free energy consists of polar (and nonpolar) terms; is the change of conformational entropy on nanobody binding, which was not considered here as the binding epitope on the RBD is very stable and the comparison was performed internally. The decomposition of the binding free energy to the relative energy contribution from individual residues was performed using the MMPBSA.py module in AMBER18 (68) . The relative contribution to the binding energy from mutated residues observed in VOC were plotted as heatmap.

The MPD, 0.1M cacodylate pH 6.5, 5% (w/v) polyethylene glycol 8000 for the 2-31 complex. Collected data were processed with HKL2000 (71). X-ray structures were solved by molecular replacement (MR) using PHASER (72) with original MR models for the RBD and Nanobody from PDB 7JMW (73) and PDB 7KN5 (19) . Iterative model building and refinement were carried out in COOT (74) and PHENIX (75) , respectively.

The epitope propensity profile of SARS-CoV-2 RBD (PDB 7jvb) was computed by ScanNet, a state-of-the-art geometric deep learning model for structure-based protein binding site prediction (76) . We used the B-cell epitope network (ScanNet-BCE) without evolutionary information that was not trained on any SARS-CoV-1/2 antibody/antigen complex.

Dataset preparation. We collected all viral antibody -antigen complexes in PDB, as listed by SabDab (77) (release: 10/19/2021). Antigens were clustered at 70% sequence identity with a minimum length coverage of 15% using CD-HIT (78), the Bio.align pairwise sequence alignment module and CATH domain identifiers.

Briefly, we found that (i) ngram-based clustering using CD-HIT with default parameters overestimated the number of clusters, while (ii) computing all the entries of the pairwise sequence similarity matrix was intractable for our set of several thousands structures. We instead proceeded as follows: for a given sequence identity cut-off T (e.g. 100), sequences were clustered with CD-HIT, and the resulting representatives were further clustered at T-20. For each pair of T-representatives with identical CATH identifier or same T-20 cluster, the sequence identity and coverage were evaluated by pairwise alignment and the corresponding T-clusters were merged if necessary. The process was iterated at T=100%, 95%, 90%, 70% sequence identity cut-offs and yielded satisfactory clusters. We further grouped together the following antigen clusters that had lower sequence identity but high structure similarity: (i) Influenza hemagglutinin from strains H1N1, H3N2, H5N1, H7N9, H2N2 and (ii) Envelope protein of Dengue 1, Dengue 2, Dengue 4 and Zika. Only clusters with at least 7 unique antibodies were retained for further analysis, yielding 11 viral antigens.

Antibody hit rate calculation. We constructed a multiple sequence alignment for each antigen cluster using MAFFT (79) and selected a representative structure with highest structure coverage and resolution. For each column of the alignment, the antibody hit rate was calculated as the fraction of unique antibodies binding it. For each complex, we identified the epitope residues as the antigen residues having at least one heavy atom within 4Å of at least one antibody heavy atom. Our analysis was performed on the antigen surface residues (relative accessible surface area >= 0.25, computed within the biological assembly for multimeric antigens using Bio.DSSP). Finally, the column-wise antibody hit rate was projected back onto the surface residues representative structure.

For each representative antigen chain, a multiple sequence alignment was constructed by homology search on the UniRef30_2020_06 sequence database using HHBlits (80) (4 iterations, default parameters). The alignment was deduplicated, hits with high gap content (>=25% of the alignment) were discarded and the 10K best hits were retained based on sequence identity. Each sequence was assigned a weight inversely proportional to the number of similar sequences found in the alignment (90% sequence identity cut-off). The amino acid frequency at each site f i (a) was subsequently calculated and the residue-wise conservation score was defined as C i = ln (20) -S(f i ) where

. Conservation scores range from 0 to ln(20) = 2.99, higher is more conserved. We checked that this protocol correlated well with the ConSurf method based on phylogenetic trees (81) . Epitope propensity scores were calculated with ScanNet-BCE.

Root mean square fluctuation of each RBD residue was calculated based on 100 ns Molecular Dynamics simulation trajectory. The simulation was run starting from the RBD structure (PDB 6lzg) using Gromacs 2020 version with the CHARMM36m force field (82) . The RBD structure was solvated in transferable intermolecular potential with 3 points (TIP3P) water molecules and ions were added to equalize the total system charge. The steepest descent algorithm was used for initial energy minimization until the system converged at Fmax < 1,000 kJ/(mol · nm). Then water and ions were allowed to equilibrate around the protein in a two-step equilibration process. The first part of equilibration was at a constant number of particles, volume, and temperature (NVT). The second part of equilibration was at a constant number of particles, pressure, and temperature (NPT). For both MD equilibration parts, positional restraints of k = 1,000 kJ/(mol · nm2) were applied to heavy atoms of the protein, and the system was allowed to equilibrate at a reference temperature of 300 K, or reference pressure of 1 bar for 100 ps at a time step of 2 fs. Altogether 10,000 frames were saved for the RMSF analysis at intervals of 10 ps. To estimate average epitope RMSF, we defined epitope residues as residues with at least one atom within 4Å from the Nb atom and averaged RMSF over epitope residues.

The phylogenetic analysis was performed to 1) 19 Sarbecovirus RBD sequences (Fig. 1a) 2) 100 psNb CDR3 sequences ( fig. S2a ) and 3) 32 SEC group B psNb and 3 previously characterized benchmark Nbs (Nb34, Nb95 and Nb105) CDR3 sequences (Fig. 4a) . Sequences were aligned by MUSCLE (83) with default parameters. The phylogenetic tree was then constructed by the MEGA (84) using the maximized likelihood estimation method.

To calculate Sarbecovirus RBD conservation with respect to SARS-CoV-2, 18 Sarbecovirus RBD sequences mentioned above were aligned to SARS-CoV-2 RBD sequence. After alignment, each SARS-CoV-2 RBD residue was compared to corresponding residue in other RBD sequences. An identical residue to that in SARS-CoV-2 is considered a match. The conservation for each RBD residue is calculated by the number of matches over 18.

An RBD residue and an Nb residue were defined in contact if the distance between any pair of their atoms was lower than a threshold of 4 Å. The Nb contact value of each RBD residue is calculated as the sum of all the Nb contacts.

The solvent-accessible surface area (SASA) of molecules was calculated by FreeSASA (85) . The buried surface area in the case of the Nb-RBD complex was then calculated by equation:

The Nb epitope residues were extracted based on the method described above. The centroid of the Nb epitope residues is defined by the center of mass of atoms. Similarly, the centroid of receptor binding sites(RBS) was extracted. The distance between Nb epitope and RBS was calculated based on the distance between two centroids.

The viral fitness score was obtained from (31) by evaluating the mutational effects on RBD expression level.

The fitness score of each RBD residue is the averaged value of mutating to any other amino acids. The viral fitness score of epitopes was calculated by averaging fitness score over epitope residues.

Based on the crystal structure of complex ACE2 and SARS-CoV-2 RBD contain seven (N53, N90, N103, N322, N432, N546, N690) and one (N343) N-glycosylation sites, respectively. A heterogeneous glycosylated system was set up for the complex based on previous study (29). The glycosylated ACE2:RBD complex was modeled by the Glycan Modeler module of the CHARMM-GUI webserver (86). Interfaces were extracted from PDB Nb structures. The number of Nb-interacting atoms per each VOC residue was counted to generate the plot. The psNbs identified in this study are bolded. S20 . Scatter plots of antibody hit rates against conservation scores for surface residues for 11 antigens. A negative trend is found for most antigens. Notable outliers include the envelope protein of HIV and the genome polyprotein of Hepatitis C; we speculate that this is due to (i) over-representation of broadly neutralizing antibodies in the PDB and/or (ii) extensive glycosylation.

. Scatter plots of ScanNet epitope propensity scores against conservation scores of surface residues for 11 antigens. A negative trend is observed between the conservation score and the ScanNet epitope propensity score which was calculated from antigen structure only. This suggests that the association between conservation and antibody hit rate arises solely from structural properties.

Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases

Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic

COVID super-immunity: one of the pandemic's great puzzles

High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape

Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptorbinding domain by structure-guided high-resolution serology

Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape

A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Broad sarbecovirus neutralization by a human monoclonal antibody

Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2

Integrative proteomics identifies thousands of distinct, multi-epitope, and high-affinity nanobodies

Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants

Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape

A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19

NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies

The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates

Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

-47) was covalently coated to the flow cell (Fc) 2 of a CM5 sensorchip. Fc1 of the sensorchip was non-coated as control. 1 µM deglycosylated RBDSARS-CoV-2 in the HBS-EP buffer was injected to the surface at 20 µl/min for 3 mins with dissociation for 3 mins, followed by a sequential injection of 1 µM glycosylated RBDSARS-CoV-2

Comparison of overall structures of 2-31 and 1-21 bound to SARS-CoV-2 RBD

Glycans in SARS-CoV-2 RBD and ACE2 are shown in sticks and labeled with their corresponding asparagine(N) position number. CC12.1 was used to complex with 2-31 and SARS-CoV-2 to obtain diffraction-quality crystals for structure determination. 2-31 is shown in dark red, 1-21 in beige, RBD in light gray

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

A robust pipeline for rapid production of versatile nanobody repertoires

Automated electron microscope tomography using robust prediction of specimen movements

cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination

Non-uniform refinement: adaptive regularization improves singleparticle cryo-EM reconstruction

3D variability analysis: Resolving continuous flexibility and discrete heterogeneity from single particle cryo-EM

Prevention of overfitting in cryo-EM structure determination

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Features and development of Coot

ColabFold -Making protein folding accessible to all. bioRxiv, 2021

Real-space refinement in PHENIX for cryo-EM and crystallography

Structural analysis of glycoproteins: building N-linked glycans with Coot

Structure visualization for researchers, educators, and developers

New tools for automated high-resolution cryo-EM structure determination in RELION-3

The Amber biomolecular simulation programs

Scalable molecular dynamics with NAMD

Amino-Acid-Specific Protein Backbone Parameters Trained against Quantum Mechanics Energy Surfaces in Solution

GLYCAM06: a generalizable biomolecular force field. Carbohydrates

Comparison of simple potential functions for simulating liquid water

Constant pressure molecular dynamics algorithms

Constant pressure molecular dynamics simulation: The Langevin piston method

Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes

Converging free energy estimates: MM-PB(GB)SA studies on the proteinprotein complex Ras-Raf

Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models

MMPBSA.py: An Efficient Program for End-State Free Energy Calculations

A highly conserved neutralizing epitope on group 2 influenza A viruses

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Processing of X-ray diffraction data collected in oscillation mode

Phaser crystallographic software

Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity

PHENIX: a comprehensive Python-based system for macromolecular structure solution

ScanNet: An interpretable geometric deep learning model for structure-based protein binding site prediction. bioRxiv

SAbDab: the structural antibody database

CD-HIT: accelerated for clustering the next-generation sequencing data

Parallelization of MAFFT for large-scale multiple sequence alignments

HH-suite3 for fast remote homology detection and deep protein annotation

ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules

CHARMM36m: an improved force field for folded and intrinsically disordered proteins

MUSCLE: a multiple sequence alignment method with reduced time and space complexity

Molecular Evolutionary Genetics Analysis across Computing Platforms

FreeSASA: An open source C library for solvent accessible surface area calculations

CHARMM-GUI: a web-based graphical user interface for CHARMM

MolProbity: More and better reference data for improved all-atom structure validation